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INTRODUCTION 
Metabolic syndrome is combination of disorders 
related with altered state of metabolism of 
Carbohydrates, Proteins and Lipids in human body. 
HYPERLIDEMIA is one of these disorders. High 
plasma level of lipids taken by food or synthesized in 
form of cholesterol by liver are risk factors to 
development of HYPERLIPIDEMIA
1-3
.  Total 
cholesterol and LDL-cholesterol are main factors 
causing oxidation of LDL leading to formation of 
atherosclerotic plaques, which causes coronary artery 
disease, hypertension, CCF, angina and cardiac 
arrhythmias
4
. Conventionally used Antihyperlipidemic 
drugs include HMG-CoA reductase inhibitor 
STATINS, Niacin, Bile acid binding resins, and 
Fibrates. Their compliance is low due to their 
unwanted effects in different parts of body or their 
therapeutic dose recommended
5
.   Zingiber Officinale 
(Ginger) contains Carbohydrates, fats, proteins, dietary 
fibers, zinc, sodium, potassium, phosphorus, 
manganese, magnesium, iron, calcium, vitamin C, E, 
and B-1,2,3,5,6, and vitamin B-9
6-10
.  Dietary fibers, 
vitamin C, vitamin E and vitamin B-3 (Niacin) in 
Zingiber Off. are responsible to cause hypolipidemic 
effects of this herb
11
.  These vitamins are responsible 
for hypolipidemic effects of the herb, which act as 
antioxidant. In many research studies it has been 
proved that free radical formation (ROS) is lowered by 
using these vitamins. In various studies it has also been 
proved that vitamin B-3, C and E utilize these Reactive 
Oxygen Species (ROS) synthesized in many metabolic 
pathways leading to lowering of oxidative stress, 
atherosclerosis, CAD and its consequences like 
hypertension, CCF, angina, MI, and cardiac 
arrhythmias
12
.  
SUBJECTS & METHODS 
The research work was conducted from March 2015 to 
May 2015. Eighty male and female patients age range 
from 18 to 65 years with high lipid profile were 
selected in the research work conducted at General 
Hospital, Lahore-Pakistan.  
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ABSTRACT 
Hyperlipidemia had have proved in many research studies causing atherosclerosis, coronary artery disease, angina and 
myocardial infarction. Hypolipidemic drug’s low compliance made medicinal herbs to replace conventional hypolipidemic 
agents for treating primary or secondary hyperlipidemic patients. Zingiber Officinale (Ginger) is one of those medicinal 
herbs.  This research was conducted at General Hospital Lahore Pakistan from March to May 2015. It was single-blind 
placebo controlled study. Inclusion criteria was primary and secondary hyperlipidemic patients age range from 18 to 65 
years. Male and female patients were included in this work. Randomly selected eighty patients were divided in two equal 
numbers. Group-I was tested group and Group-II was on placebo therapy. Their base line values of LDL-cholesterol and 
plasma total cholesterol were measured in Biochemistry laboratory of the Hospital.  When used in 40 hyperlipidemic 
patients this herb’s paste preparation reduced LDL-cholesterol and plasma total cholesterol significantly. Mean values of 
LDL-cholesterol and plasma total cholesterol with SEM before and after treatment were calculated and analyzed 
biostatistically by using SPSS version 5.0. P-values >0.05 were used for non-significant change in parameters. P-values 
<0.01 and <0.001 were used for significant and highly significant changes respectively.  
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The study was single blind placebo controlled. Duration 
of study was 12 weeks. Explained and written consent 
was taken from all participants.  Research work on 
human beings and its objectives were approved from 
Ethical Committee of the Hospital. Exclusion criteria 
was peptic ulcer disease, alcohol abuse, cigarette 
smoking, any liver, or renal disease and thyroid 
dysfunction. Patients were divided in two groups, i.e.  
group-I (n=40) was advised to take  equally divided  
dose of 5 grams of Pasted Ginger with each meal thrice 
daily for three months.  Group-2 was on placebo 
therapy, provided Capsules containing grinded wheat, to 
take thrice daily for three months. To be tested 
parameters of LDL-cholesterol and Total-cholesterol 
were determined in Biochemical laboratory of the 
Hospital. Serum total cholesterol was estimated by the 
enzymatic calorimetric method. Serum LDL-cholesterol 
was calculated by Friedwald formula
5
 (LDL-Cholesterol 
= Total Cholesterol-(Triglycerides/5 +HDL-
Cholesterol). Data were expressed as the mean ± SEM 
and paired “t” test was applied to determine statistical 
significance as the difference. A probability value of 
<0.05 was considered as non-significance and P<0.001 
was considered as highly significant change in the 
results, while p<0.01 was labeled as significant 
alteration in tested parameter.  
RESULTS 
After three months, when data were ready to analyze, it 
was observed that 3 patients withdrew to take Ginger 
due to their personal problems, and low compliance of 
the drug. In three months therapy by Ginger, LDL-
cholesterol reduced from 199.08±2.29 mg/dl to 
187.56±1.96 mg/dl,  which is highly significant change 
in the parameter. Serum total cholesterol at baseline was 
279.66±1.22 mg/dl which reduced to 268.95±1.11 mg/dl 
after three months therapy. These changes are significant 
statistically. In placebo group LDL-Cholesterol, and 
serum total cholesterol reduction was 0.7 mg/dl, and 0.2 
mg/dl respectively. All these changes are non-significant 
(p-value >0.05). Detailed changes are shown in table. 
 
Table Explaining changes in parameters before and after treatment with Zingerber Officinale 
 ZINGEBER Off (n=37) Placebo (n=40) 
Before TC    279.66±1.22 
LDL-c  199.08±2.29 
Tc   268.95±1.11 
Ldl-c   187.56±1.96 
After TC    267.21±1.09 
LDL-c   178.29±1.08 
Tc   267.01±1.11 
Ldl-c   177.64±1.34 
Change TC   12.5 
LDL-c   20.8 
Tc   0.2 
Ldl-c   0.7 
Change in % TC   4.5 
LDL-c   10.4 
Tc    0.1% 
Ldl-c   0.4% 
p-value TC   <0.01 
LDL-c   <0.001 
Tc   >0.05 
Ldl-c  >0.05  
 
KEY:    P-value <0.001 = highly significant, P-value <0.01= significant, p-value >0.05 = non-significant changes in lipid profile. 
Total-cholesterol-c and LDL-c values are measured in milligrams per DL. ‘n’ indicates number of patients (sample size) in tested 
and placebo group.  All parameter’s mean values and their difference between before/ after treatment values are measured in mg/dl. 
TC stands for total plasma cholesterol, LDL-C stands for low density lipoprotein cholesterol.  
 
DISCUSSION  
Simply, dyslipidemia is related with morbidity and 
mortality though out the world due to its complication 
like atheroma formation, CAD, hypertension, angina 
and myocardial infarction. In allopathy Hyperlipidemia 
either secondary or primary is simple to treat, but broad 
canvas of pharmacological effects of allopathic drugs 
made them unpopular in human population. Simply it is 
low drug-compliance. Herbal medicinal preparations are 
on way to replace unpopular allopathic drugs for 
treating Hyperlipidemia. Medicinal herb Zingiber Off. 
contain vitamin C, vitamin E, and vitamin B-3 which act 
as antioxidant agents. In our research work LDL-
cholesterol reduction by three months treatment by 
Zingiber Off. was 10.4%. When anlalysed statistically it 
was highly significant change.  In total cholesterol this 
reduction in 37 hyperlipidemic patients was 4.5%, 
which is significant when analyzed biostatistically. Our 
results are being supported when we compare these 
changes with results of work conducted by Bordia A et 
al
13
 who proved that Ginger can reduce LDL-cholesterol 
higher than plasma total cholesterol when used in 
primary or secondary sufferer patients of 
Hyperlipidemia. Janssen P et al
14
 has also explained 
being main target of LDL oxidation which is 
independent risk factor for development of coronary 
artery disease. Srivastava KC
15
 proved lesser effects of 
Ginger utilization by 50 hyperlipidemic patients 
suffering from secondary Hyperlipidemia. He proved 
that Ginger can reduce only five to six percent LDL-
cholesterol and plasma Total-cholesterol, respectively in 
secondary Hyperlipidemia. Reason for this contrast in 
two studies are obviously due to selective sample i.e. 
patients suffering from secondary Hyperlipidemia. Shoji 
N et al
16
 have explained that patients enjoying sedentary 
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life, alcohol abusers, cigarette smokers and fond of 
eating junk foods are more prone to develop too much 
oxidative stress as compared to patients of primary 
Hyperlipidemia. For most patients, the root causes of the 
metabolic syndrome are thought to be poor nutrition, 
inadequate physical activity, and subsequent increases in 
body weight. Obesity is associated with insulin 
resistance and the syndrome's cluster of other metabolic 
disorders. However, there are many interrelated factors 
that are thought to be important in the development of 
metabolic syndrome.  
CONCLUSION 
It was concluded from this research work that 
hypolipidemic herbal medications can play major role in 
prevention of atherosclerosis, coronary artery disease 
(CAD), Congestive Cardiac Failure, Angina, and 
Myocardial Infraction if taken in specific amount by 
primary or secondary hyperlipidemic patients. It is also 
recommendation for pharmaceutical industries that 
isolated active ingredients of Ginger can be used to 
prepare new generation of hypolipidemic drugs.  
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